RT Journal Article
T1 Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.
A1 Philis-Tsimikas, Athena
A1 Billings, Liana K
A1 Busch, Robert
A1 Portillo, Cristobal Morales
A1 Sahay, Rakesh
A1 Halladin, Natalie
A1 Eggert, Sarah
A1 Begtrup, Kamilla
A1 Harris, Stewart
K1 GLP-1 analogue
K1 SGLT2 inhibitor
K1 insulin therapy
K1 liraglutide
K1 randomized trial
K1 type 2 diabetes
AB To investigate the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as add-on to sodium-glucose co-transporter-2 (SGLT2) inhibitor therapy. In this 26-week, phase IIIb, open-label, parallel-group, treat-to-target trial, conducted at 74 sites in 11 countries, insulin-naïve people aged ≥18 years with glycated haemoglobin (HbA1c) 53-97 mmol/mol (7.0-11.0%), body mass index 20-40 kg/m2 and inadequately controlled type 2 diabetes (T2D) on SGLT2 inhibitor ± oral antidiabetic drugs were randomized 1:1 to once-daily IDegLira or IGlar U100, both as add-on to existing therapy. The primary endpoint was change in HbA1c from baseline to week 26. A total of 210 participants were randomized to each treatment arm. Mean HbA1c reductions were 21 mmol/mol (1.9%-points) with IDegLira and 18 mmol/mol (1.7%-points) with IGlar U100; confirming non-inferiority (P  The favourable safety and efficacy profile of IDegLira in people with uncontrolled T2D on SGLT2 inhibitors, and lower weight gain and hypoglycaemia risk versus IGlar U100, suggest that clinicians should consider IDegLira initiation in this population.
YR 2019
FD 2019-04-04
LK http://hdl.handle.net/10668/13562
UL http://hdl.handle.net/10668/13562
LA en
DS RISalud
RD Apr 6, 2025